Research programme: nuclear hormone receptor modulators - Galapagos/Eli LillyAlternative Names: Nuclear hormone receptor modulators research programme - BioFocus/Eli Lilly
Latest Information Update: 03 Feb 2009
At a glance
- Originator Eli Lilly; Galapagos NV
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 03 Feb 2009 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 14 Jan 2008 Biofocus DPI and Eli Lilly have extended their drug discovery agreement until the end of 2008
- 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV